Compare Grab Holdings Ltd. (GRAB) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Grab Holdings Ltd. vs Vertex Pharmaceuticals Incorporated — how do they compare? Grab Holdings Ltd. trades at $3.74 (market cap $15.26B), while Vertex Pharmaceuticals Incorporated trades at $529.62 (market cap $134.25B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 8.8× Grab Holdings Ltd.'s market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Grab Holdings Ltd. nearer its low. Which is the better fit depends on your goals.
| GRAB | VRTX | |
|---|---|---|
Market Cap | $15.26B | $134.25B |
Sector | Technology | Health |
52-Week High | $6.45 | $529.65 |
52-Week Low | $3.27 | $376.62 |
Enterprise Value | $10.99B | $128.37B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Grab Holdings Ltd.
Grab Holdings Limited operates as a holding company. The Company, through its subsidiaries, develops delivery management, mobility, financial services, and enterprise software solutions. Grab Holdings serves customers worldwide.
Read more on GRAB →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
